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Abstract Few consistent etiological factors have been
identiﬁed for primary brain tumors. Inverse associations to
asthma and low levels of varicella-zoster virus, immuno-
globulin (Ig) levels in prevalent cases have indicted a role
for the immune system in the development of glioma.
Because samples from prevalent cases of glioma could be
inﬂuenced by treatments such as steroids and chemother-
apy, we investigated pre-diagnostic samples from three
large Scandinavian cohorts. To test the hypothesis that
immune response levels to these viruses are associated
etiologically with glioma risk, we investigated pre-
diagnostic immunoglobulin levels for cytomegalovirus
(CMV), varicella-zoster virus (VZV), adenovirus (Ad), and
Epstein-Barr virus (EBV) including the nuclear antigen
(EBNA1) using plasma samples from 197 cases of adult
glioma and 394 controls collected from population-based
cohorts in Sweden and Denmark. Low VZV IgG levels
were marginally signiﬁcantly more common in glioma
cases than the controls (odds ratio (OR) = 0.68, 95% CI
0.41–1.13) for the fourth compared with the ﬁrst quartile
(p = 0.06 for trend). These results were more prominent
when analyzing cases with blood sampling at least 2 years
before diagnosis (OR = 0.63, 95% CI 0.37–1.08)
(p = 0.03). No association with glioma risk was observed
for CMV, EBV, and adenovirus.
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Introduction
Gliomas are the most common primary malignant brain
tumor. Although glioma treatment strategies—surgery,
irradiation, and chemotherapy—have improved, the prog-
nosis is still poor compared with many other human
malignancies [1, 2]. Recently, the concomitant use of
chemotherapy and irradiation and the use of the antian-
giogenic treatment bevacizumab have improved prognosis
[3]. As few etiological factors for glioma have been iden-
tiﬁed, few effective preventive strategies have been
developed [4, 5]. The only conﬁrmed risk factors are high
dose of ionizing radiation and some rare hereditary pre-
disposing conditions that are only found in less than 5% of
all glioma cases [6, 7]. A familial aggregation of gliomas
has been observed in several studies [8–10] and recently
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ciated with glioma risk [11, 12].
The question if viruses might cause, promote, or prevent
human brain tumors is of great interest as viruses have been
proven to cause several other types of cancers [13]. Earlier
studies have shown evidence of viral DNA or proteins in
tumor tissue for example JCV and SV40 [14, 15]. CMV
and adenoviruses have also been reported to be present in
brain tumor tissue [16–20]. It is, however, unclear whether
their presence is due to the immunosuppressive environ-
ment in the tumor, making it a predilection site for viruses,
or whether the presence of viruses in the tumor is due to an
etiological impact.
Immunologic response to viral infections may be asso-
ciated with the risk of developing glioma or glioblastoma
[1]. Statistically signiﬁcant inverse associations of adult
glioma to both history of chickenpox and immunoglobulin
G antibodies against varicella-zoster virus have been
reported [21–23]. Patients with glioma and glioblastoma
had levels of anti-varicella-zoster virus immunoglobulin G
signiﬁcantly lower than controls, indicating that the level
of immune response to viruses may play a role in glioma
induction or progression. Although some studies specu-
lated whether the lowered IgG-levels preceded tumor
diagnosis, this has not been clariﬁed. Furthermore, several
studies have shown an inverse association between occur-
rence of allergic diseases and brain tumors, a ﬁnding that
indicates that the immune system function is important for
glioma etiology [24–26]. In this study, we investigated the
association between IgG levels of four viruses in pre-
diagnostic samples and whether these levels were associ-
ated with glioma risk.
Materials and methods
Study population
This case–control study was based on 197 glioma cases and
394controlsfromthreecohorts:NorthernSwedenHealthand
Disease Study—The Medical Biobank (NSHDS) (79 glioma
cases and 158 controls); the Malmo ¨ Diet and Cancer Study
(MDCS) (45 glioma cases and 90 controls); and the Diet,
Cancer,andHealthcohortfromCopenhagen(73gliomacases
and146controls).Thecontrolswerematchedforage,sex,and
cohort. The male/female distribution was 47.7%/52.3%, and
the median ages at blood sampling were 55.4 years in cases
and 55.3 in controls. Table 1 describes the cases and controls
from the different cohorts. The diagnosis of glioma was
identiﬁed through linkage to the local cancer registries. The
registries have close to 100% coverage of cancer diagnoses
sincebothcliniciansandpathologistsinSwedenandDenmark
are legally obligated to report cancer diagnoses.
For the Swedish cases, we were able to receive classiﬁ-
cation of the tumors according to SNOMED (Systematized
Nomenclature of Medicine). A total of 61 glioblastoma
(SNOMED 94403), 8 astrocytoma grade 1–2 (SNOMED
94003, 94203, 94213), 32 astrocytoma grade 3 (SNOMED
94013), 14 oligodendroglioma (SNOMED 94503, 94513,
94603), 2 oligoastrocytoma (SNOMED 93823), and 5
malignant glioma (SNOMED 93803), were seen in the
Swedish cases. SNOMED classiﬁcation was not available
on the cases from Copenhagen.
Northern Sweden health and disease study
NSHDS is a population-based cohort consisting of blood
samples and questionnaires from three subcohorts [27]:
The Va ¨sterbotten Intervention Program (VIP); the Va ¨ster-
botten Mammary Screening Program; and the Northern
Sweden MONICA (Monitoring Trends and Determinants
in Cardiovascular Disease) Project. By June 2006, the VIP
cohort comprised 94,630 samples from 74,690 individuals.
These individuals were asked to participate in a health
study the year they turned 40, 50, and 60. Since 1995,
blood samples were collected for the Mammary Screening
Program and have been added to the VIP cohort. From
1997, repeated screening was started in the Mammography
Screening Program in the age group 50–69. The MONICA
project provided 11,000 random blood samples from 7,500
individuals ranging from 25 to 64 years old. All cohorts
were population based and contained 166,000 randomly
Table 1 Descriptive table showing the male/female ratio (numbers and percentages for cases shown, and percentages for controls are the same
as for cases) and median age at blood sample for the whole cohort and each cohort
All NSHDS Malmo ¨ Copenhagen
Case Control Case Control Case Control Case Control
All 197 394 79 158 45 90 73 146
Male 94 (47.7%) 188 33 (41.8%) 66 25 (55.6%) 50 36 (49.3%) 72
Female 103 (53.3%) 206 46 (58.2%) 92 20 (44.4%) 40 37 (50.7%) 74
Median age at blood sample 55.4 55.3 50.1 50.1 58.1 58.0 57.5 57.6
1260 Cancer Causes Control (2011) 22:1259–1266
123selected men and women and 278,000 sample occasions.
Seventy-nine individuals were later diagnosed with a
glioma [28].
The Malmo ¨ Diet and Cancer Study
The Malmo ¨ Diet and Cancer Study (MDCS) is a popula-
tion-based prospective cohort study. Between 1991 and
1996, men and women between the ages of 44 and 77 were
recruited with the main goal to study the impact of diet on
cancer incidence and mortality. In all, 28,098 blood sam-
ples were stored in a medical biological bank. Regular
follow-up with the national registries of mortality and
cancer was done, and 45 individuals from the cohort were
later diagnosed with a glioma [29, 30].
Diet, cancer, and health—Denmark
The Diet, Cancer, and Health study is a population-based
prospective cohort study from Denmark where 80,996 men
and 79,729 women were invited to participate between
December 1993 and May 1997. The study included indi-
viduals between 50 and 64 years of age, born in Denmark,
and with no diagnosis of cancer registered in the Danish
Cancer Registry. Blood samples were obtained from
57,053 participants. From these individuals, 73 were later
diagnosed with glioma [31].
The controls were collected from living individuals with
no history of primary brain tumor at the time of case
diagnosis and matched for age, gender, and calendar year
of sampling. All individuals had a written informed consent
and the study was approved by the local ethical committee
at Umea ˚ University.
Laboratory methods
IgG antibodies for adenovirus, CMV, and VZV were ana-
lyzed, by in-house enzyme-linked immunosorbent assays
(ELISA), at the Department of Virology at Umea ˚ Univer-
sity. The origins of viral antigens used were for adenovirus
a mixture of two local strains of Ad 3 and Ad 5, for CMV
laboratory strain CMV 169 and for VZV a local strain. The
analyses were blinded and performed in duplicate in a pair
of wells coated with viral antigen and control antigen. In
each run, high and low positive controls and negative
controls were included. The sera were analyzed in a ﬁnal
dilution of 1/441, in which dilution there is a high corre-
lation to antibody levels expressed as titers. The antibody
activity in the single dilution of the sample was expressed
in arbitrary units (AU), i.e., as a percentage of the net-
absorbance (absorbance of virus-coated well) of the high
positive control. Samples with\10 AU were negative. The
IgG-anti-EBNA-1 response to EBV was measured using a
commercial ELISA from Biotest Germany according to the
manufacture’s instructions. The antibody activity of the
sample was expressed in AU as a percentage of the positive
control and the manufacturer’s cut-off value for presence
of antibodies was used.
The IgG response to EBV viral capsid antigen (VCA)
was analyzed by immunoﬂourescence assay in a high
screening dilution (1/320) using butyric acid-stimulated
P3HR1 lymphoma cells. The samples were blinded to
case–control status and an experienced microscopist read
all the samples (PJ). The ﬂuorescence activity grading was
aggregated to three categories: ‘‘low’’ (negative in 1/320
dilution), ‘‘intermediate’’ (weak positive), and ‘‘high’’
(intermediate and strong positive). Negative samples in
1/320 dilution were identiﬁed by re-analysis in 1/20 dilu-
tion. VCA was not used in the statistical analyses except
for ruling out active infection. All methods are accredited
at The Swedish Board for Accreditation and Conformity
Assessment.
Statistical methods
The proportions of cases and controls that were positive for
the different immunoglobulin G and the mean age at blood
sample in these groups were calculated and were estimated
separately for glioma and for glioblastoma (SNOMED
94403). In the glioblastoma group, only the Swedish cases
were available for analysis as the SNOMED code was not
available for the Danish cases. The IgG antibody levels
were divided into four same-sized quartiles, and cut-offs
were based on IgG levels in controls. Binary logistic
regression was used to compare the quartiles between cases
and controls, and the lowest quartile was set as a reference.
All odds ratios (OR) were adjusted for sex, cohort (Umea ˚,
Malmo ¨, and Denmark), and age at blood sampling. Sepa-
rate analyses were also performed on cases with blood
samples taken at least 2 years before diagnosis to omit any
bias associated with the preclinical phase of the disease.
The correlation between genotypes and IgG quartiles was
performed by chi-square test using Fisher’s exact test and
p\0.05 was identiﬁed as the level for signiﬁcance. SPSS
software (v. 17) was used for the analyses.
Results
Overall, there were high levels of seropositivity for the
studied viruses, varying from 85.2 to 100%, and this result
was similar in cases and controls (Table 2). The analyses
were successful for close to 100% of the subsets of
immunoglobulin. The mean age at blood samples did not
differ signiﬁcantly between the cases and the controls
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glioma and glioblastoma cases and controls, but a non-
signiﬁcant trend of lower VZV odds ratios was seen in the
second, third, and fourth quartile (OR = 0.85, 95% CI
0.53–1.36; OR = 0.74, 95% CI 0.45–1.23; and OR =
0.68, 95% CI 0.41–0.13, respectively) (p = 0.06)
(Table 4). The trend test was signiﬁcant when restricting
the analyses to glioma cases with a latency of more
than 2 years from sampling to glioma diagnosis (total 164
cases) (p-trend test, p = 0.03) (Table 5).
Discussion
To our knowledge, the present study is the ﬁrst compre-
hensive study where virus-serology for EBV, CMV, VZV,
and adenovirus is analyzed in samples from glioma/glio-
blastoma cases taken before diagnosis. This has previously
been studied in astrocytoma for JC virus, BK virus, and
simian virus 40, but no association to risk was found [32].
We found that immunoglobulin G to varicella-zoster
virus was lower in cases versus controls especially in
samples taken at least 2 years before diagnosis, a ﬁnding
that indicates there might be an etiological association. No
association between antibody levels for CMV, EBV, or
adenoviruses and glioma risk was found.
Varicella-zoster virus (VZV) is neurotropic, and viruses
remain permanent in neural ganglia after a primary infec-
tion. Furthermore, several studies have shown that immu-
noglobulin G levels of VZV are lower in serum from
glioma cases, especially glioblastoma cases, compared
with controls [21–23]. This lower level of VZV in serum
from glioma cases could be because the tumor itself or the
early treatment of the tumor inﬂuenced the immune
response levels. Our data show a signiﬁcant trend for lower
VZV IgG levels especially in cases with blood samples
taken more than 2 years before diagnosis, indicating that
this could be a true etiological association. A medical
history of asthma and allergies have been inversely corre-
lated to glioma in several case–control studies indicating
that the immune system may be a key player in glioma
development [33, 34]. The biological reasons for this
association are currently unknown. A previously stated
theory is that a strong immune system more easily could
detect viruses and therefore be able to inhibit the growth of
small cancer cell clusters [22]. That can be demonstrated
by the recent study showing that T-cell inﬁltration impacts
on glioblastoma survival [35].
Table 2 Incidence of subjects positive for immunoglobulin G antibodies, in adenovirus, cytomegalovirus, Epstein-Barr virus, and varicella-
zoster virus in the Umea ˚, Malmo ¨, and Copenhagen cohorts
All subjects Controls Glioma cases Glioblastoma Sweden
No. positive/
total no.
Positive
(%)
No. positive/
total no.
Positive
(%)
No. positive/
total no.
%
positive
p-
value
No. positive/
total no.
%
positive
p-
value
a
Immunoglobulin G antibodies
Adenovirus 584/589 99.2 388/393 98.7 196/196 100 0.18 61/61 100 1.00
Cytomegalovirus 504/589 85.6 335/393 85.2 169/196 86.2 0.80 53/61 86.9 1.00
Epstein-Barr
virus
511/587 87.1 347/391 88.7 164/196 83.7 0.09 54/61 88.5 0.15
Varicella-zoster
virus
582/589 98.8 389/393 99.0 193/196 98.5 0.69 59/61 96.7 0.26
Cases/controls and Swedish cases (Umea ˚ and Malmo ¨) with glioblastoma shown separately. Information on tumor subtypes was not available for
the cases from Copenhagen. No signiﬁcant difference in numbers positive between cases and controls
a Controls from Copenhagen excluded in the analysis
Table 3 Mean ages at blood sample for cases and controls from the
Umea ˚, Malmo ¨, and Copenhagen cohorts
Positive Negative
Mean
age
(years)
No. of
Subjects
Mean
age
(years)
No. of
Subjects
Immunoglobulin G antibodies
Controls
Adenovirus 54.7 389 58.7 5
Cytomegalovirus 54.8 336 54.6 58
Epstein-Barr virus
a 54.6 347 56.7 44
Varicella-zoster
virus
54.7 390 59.2 4
Cases
Adenovirus 54.8 197 0
Cytomegalovirus 54.7 170 55.4 27
Epstein-Barr virus
a 55.0 164 53.8 32
Varicella-zoster
virus
54.7 194 60.3 3
Positive or negative for immunoglobulin G antibody levels for ade-
novirus, cytomegalovirus, Epstein-Barr virus, and varicella-zoster
virus. There are no differences in mean age for cases and controls as
the controls are matched to cases on age and year of blood sample
a Based on immunoglobulin G antibody levels analyzed using EBNA
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our study as well as in previous studies.
Many reports have been published concerning poten-
tially oncogenic viruses, notably some herpes viruses such
as human cytomegalovirus (HCMV), varicella-zoster virus
(VZV), Epstein-Barr virus (EBV), and adenoviruses.
Human cytomegalovirus (HCMV) is a ubiquitous herpes
virus that is of particular interest and has long been sus-
pected to play a role in the development of human cancers
[36]. This virus has an afﬁnity for glial cells and may
possibly play an important role in glioma etiology. This
afﬁnity has been shown to inﬂuence glioma cells in several
ways that might contribute to tumor progression, resulting
in altered tumor cell properties such as reduced apoptosis,
increased cell invasion, telomerase activation, and
enhanced angiogenesis [37, 38]. A study published in 2002
reported that human cytomegalovirus (HCMV) gene
products and nucleic acids were present in all 27 glioma
samples investigated but not in other brain tissue [39].
Recently, this ﬁnding has been conﬁrmed by other research
groups [17, 18]. Although a causal relationship between
HCMV and human cancer has not been clearly proven, it is
obvious that the virus may have a potential to promote
oncogenesis or tumor progression in human cells.
Epstein-Barr-virus infections (EBV) have shown a clear
association with human malignancies and some CNS
tumors [40]. An increased risk for primary central nervous
system lymphoma occurs in immunodeﬁcient patients [41].
Table 4 Cases and controls odds ratios (OR) and 95% conﬁdence intervals (CI) for risk of glioma in the Umea ˚, Malmo ¨, and Copenhagen cohorts
and glioblastoma in the Umea ˚ and Malmo ¨ cohorts
Cases Glioma cases versus
controls
Glioblastoma
cases
Glioblastoma cases versus
controls
b
No. % OR (95% CI) No. % OR (95% CI)
Adenovirus, negative versus positive
Adenovirus, quartiles
1st 40 20.4 1.0 16 26.2 1.0
2nd 59 30.1 1.39 (0.85–2.28) 16 26.2 0.81 (0.37–1.79)
3rd 42 21.4 1.07 (0.63–1.81) 15 24.6 0.95 (0.42–2.12)
4th 55 28.1 1.27 (0.76–2.12) 14 23.0 0.57 (0.25–1.31)
p-trend 0.49 0.28
Cytomegalovirus, negative versus positive 1.08 (0.66–1.78) 0.97 (0.43–2.28)
Cytomegalovirus, quartiles
1st 48 24.5 1.0 15 24.6 1.0
2nd 62 31.6 1.18 (0.73–1.90) 19 31.1 0.93 (0.42–2.05)
3rd 41 20.9 1.08 (0.85–1.38) 14 23.0 0.96 (0.65–1.43)
4th 45 23.0 1.06 (0.90–1.24) 13 21.3 0.98 (0.75–1.27)
p-trend 0.67 0.36
Epstein-Barr virus
a, negative versus positive 0.64 (0.39–1.06) 0.47 (0.18–1.23)
Epstein-Barr virus
a, quartiles
1st 58 29.6 1.0 17 27.9 1.0
2nd 46 23.5 0.79 (0.49–1.29) 15 24.6 0.76 (0.34–1.70)
3rd 43 21.9 0.71 (0.44–1.16) 16 26.2 0.71 (0.33–1.55)
4th 49 25.0 0.78 (0.49–1.26) 13 21.3 0.63 (0.28–1.44)
p-trend 0.25 0.17
Varicella-zoster virus, negative versus positive 0.66 (0.15–3.01) 0.34 (0.05–2.14)
Varicella-zoster virus, quartiles
1st 55 28.1 1.0 12 19.7 1.0
2nd 55 28.1 0.85 (0.53–1.36) 26 42.6 1.71 (0.78–3.74)
3rd 43 21.9 0.74 (0.45–1.23) 16 26.2 1.08 (0.45–2.57)
4th 43 21.9 0.68 (0.41–1.13) 7 11.5 0.39 (0.14–1.08)
p-trend 0.06 0.02
All odds ratios are adjusted for cohort, sex, and age at blood sample
a Based on immunoglobulin G antibody levels analyzed using EBNA
b Glioblastoma cases from the Umea ˚ and Malmo ¨ cohorts. Copenhagen cases and controls excluded
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tumors, i.e., glioma. There is, however, no conclusive
evidence of any glial tumor associated with EBV infections
[42, 43]. Adenovirus has been shown to be neurotropic and
one study has shown it to be present in childhood brain
tumors [20]. We did not ﬁnd any evidence of an association
of EBV or adenovirus immunoglobulin levels with glioma
risk.
As the blood samples were taken before diagnosis,
antibody levels were not affected by any anti-tumor ther-
apy, an important difference compared with previous
studies. These viral infections are common in the general
population and the seroprevalences in cases and controls
were high, limiting the statistical power of this study.
Larger nested case–control studies within cohorts—using
both pre-diagnostic and post-diagnostic serological sam-
ples in combination with matched tumor sample to discern
potential effects on antibody levels by tumor tissue or
treatment effects—could provide valuable information. In
conclusion, the present study indicates that immune
response to the varicella-zoster virus might be associated
with glioma risk.
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